NCT07072247View on ClinicalTrials.gov

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2027

Conditions
Refractory Immune-mediated Platelet Transfusion RefractorinessRelapsed or Refractory Immune Thrombocytopenia
Interventions
GENETIC

CD19 and BCMA-targeted allogeneic CAR-T cells

Lymphodepletion chemotherapy followed by CD19 and BCMA-targeted allogeneic CAR-T cells infusion

Sponsors

Collaborators (1)

Allorunning Therapeutics
All Listed Sponsors
collaborator

Allorunning Therapeutics

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER